Literature DB >> 8374287

[Transfusion-induced virus infections: how great is the risk?].

W Sibrowski1, M Penner, P Kühnl.   

Abstract

The risk of infection by blood transfusions contaminated with the human immunodeficiency virus (HIV) and/or the hepatitis C virus (HCV) was dramatically reduced after the introduction of blood donor screening using specific and sensitive 2nd- or 3rd-generation enzyme immunoassays for virus antibody detection. In addition, donors selection provides the greatest safety. The strategy for safe blood supply includes medical examination and self-exclusion of donors. For example, in German blood donors, the current detection rate of HIV is between 1.36 and 1.82 confirmed positive results per 100,000 blood donations. For hepatitis C the rate of anti-HCV-positive donors is between 0.27 and 0.49%. The overall risk of HIV infection ranges from 1 in 500,000 to 1 in 3 million and that of a transfusion-associated HCV infection from 1 in 20,000 to 1 in 40,000 per transfused blood unit. From the observed virus load among German blood donors, the transfusion-associated mortality was calculated to be 1 in 260,000 per transfused blood unit. Implications are discussed resulting from this low risk of HIV and/or HCV infection by blood transfusions.

Entities:  

Mesh:

Year:  1993        PMID: 8374287

Source DB:  PubMed          Journal:  Infusionsther Transfusionsmed        ISSN: 1019-8466


  3 in total

Review 1.  History and Future of Nucleic Acid Amplification Technology Blood Donor Testing.

Authors:  Willi Kurt Roth
Journal:  Transfus Med Hemother       Date:  2019-02-05       Impact factor: 3.747

2.  Personal Freedom and Public Responsibility: Remaining Questions after First Case of HIV Transmission via Blood Transfusion in North Serbia.

Authors:  Jasmina Grujić; Nevenka Bujandrić; Pavle Banović
Journal:  Healthcare (Basel)       Date:  2022-07-27

3.  Cost-effectiveness of transfusion of platelet components prepared with pathogen inactivation treatment in the United States.

Authors:  Christopher E Bell; Marc F Botteman; Xin Gao; Joel L Weissfeld; Maarten J Postma; Chris L Pashos; Darrell Triulzi; Ulf Staginnus
Journal:  Clin Ther       Date:  2003-09       Impact factor: 3.393

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.